What is RGNX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.53B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RGNX?

P/E (TTM) is n/a and 52-week range is $5.46 to $16.19 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RGNX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RGNX?

The company profile lists revenue (TTM) near $208M, net income (TTM) near $-23.45B, EPS (TTM) near $-3.79 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Regenxbio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Rockville, Maryland, US, 63.3M shares outstanding, ISIN US75901B1070 when available from company profile and filing metadata.

Regenxbio Inc

$RGNX

Health Care · Biotechnology

IR Run Scenarios

$8.07

-0.25%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 371 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The company is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.

Employees

371

Website

regenxbio.com/

IPO

2015-09-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)